ReviewPharmaceutical science advances2026
Toxicity of nanostructures in drug delivery applications.
Review in Pharmaceutical science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Targeting the BACE1-GSK-3β Signaling Axis in Alzheimer's Disease: From Molecular Crosstalk to Nanotechnology-Based Translational Strategies.Molecular neurobiology · 2026Review
- Glucose-Responsive Nanomedicine in Diabetes Therapy: Emerging Advances and Clinical Prospects.Journal of functional biomaterials · 2026Review
- Extracellular Vesicles in Diffuse Midline Glioma: Emerging Mediators of Radiation Response and Therapeutic Resistance.Cancers · 2026Review
- Pre-Target Interception Defines Carbapenem Failure in Carbapenem-Resistant Enterobacterales: A Mechanistic Framework for Spatiotemporal Drug Reprogramming.Pharmaceutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nanostructures and nanoparticles have transformed drug delivery by enabling enhanced bioavailability, targeted therapy, controlled drug release, and improved therapeutic outcomes; however, these benefits come with complex safety and translational challenges that remain incompletely resolved. This updated review synthesizes recent advances in nanostructured drug carriers over the past five years, emphasizing unique delivery platforms such as engineered exosomes, transfersomes, cubosomes, and solid lipid nanoparticles (SLNs), and discusses their mechanisms of action, disease-specific applications, and emerging toxicity insights (e.g., neurotoxicity, pulmonary toxicity, and reproductive toxicity), which are often overlooked. Exosomes, as natural extracellular vesicles, exemplify a class of multifunctional nanocarriers that can encapsulate diverse therapeutic payloads with low inherent toxicity and favorable pharmacokinetics, and recent engineering approaches such as microfluidics, lipid modification, and surface ligand decoration have advanced their targeting precision and clinical potential, particularly for challenging indications like central nervous system infections via blood-brain barrier penetration. Moreover, this review incorporates analytical discussion of specific biological pathways and biomarkers associated with nanostructure toxicity including reactive oxygen species (ROS)-driven oxidative stress, lysosomal dysfunction, immune activation, and organ accumulation and quantitatively evaluates risk indicators across different nanocarrier classes, addressing gaps in dose, exposure duration, and aggregation state effects. Regulatory contexts and advanced predictive toxicology models, including artificial intelligence-guided quantitative structure-activity relationship (QSAR) and physiologically based pharmacokinetic (PBPK) simulations, are critically evaluated for their roles in regulatory decision-making and clinical translation. By integrating recent high-impact literature and methodical toxicity frameworks with detailed mechanistic insights, this review offers a comprehensive and up-to-date resource that delineates both therapeutic innovation and safety considerations in nanostructure-based drug delivery.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.